|
|
Office Locations:
|
6098 West Lake Rd
Cooperstown, NY 13326
| | |
|
|
|
|
|
Life Sciences & Healthcare
|
|
|
|
Cavendish Global operates in the sweet spot between Impact Venture Capital and Private Equity. Subscribers and co-investors of Cavendish include family offices, philanthropists and impact investors. Cavendish Impact Capital, and the targeted funds within it, will be managed by the current leadership of Global Bio Impact Fund under a license agreement with Cavendish Global. The firm's initial fund, The Cavendish Impact Capital Life Science Fund, will provide vital capital and a path to the marketplace for early-stage health and life science companies whose innovations have the potential to provide a transformational impact on disease prevention, diagnosis or treatment. Beyond the initial Life Science Fund, the leadership of Cavendish Impact Capital envisions future funds dedicated to provide meaningful impact on challenging issues across a spectrum of sectors. Typical investment size is 10% of total investment capital pool ($2.5-15MM).
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage
(includes "pre-seed," or
concept stage) | No Revenue |
| Early Stage | Minimal
Revenue |
Growth Stage
(also called Mid-stage) | $2M-$7M |
Expansion Stage
(also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
